National Drug Schedules

NOTE - Effective December 19, 2013, Schedule F to the Food and Drug Regulationswas repealed and replaced by a list of prescription drugs, called the Prescription Drug List. Therefore, all entries in the National Drug Schedules (NDS) whose footnote indicates that they appear in Schedule F (F1/F2) should now be considered part of the Prescription Drug List (PDL).

Entries whose footnote indicates that they are "Schedule F Recommended" (FR) should now be considered recommended for addition to the PDL. Some of the "Schedule F Recommended" entries may have been added or will shortly be added to the PDL by Health Canada, but either way these entries will continue to be listed in Schedule I of the NDS.

For more information on the Prescription Drug List, please consult the Health Canada website.

Drug Product Database
Licensed Natural Health Products Database

Print Friendly Export to CSV

Drug Name	Comment	Schedule	Date
Haemophilus influenzae type B vaccine		II	DEC / 98
Halazepam and its salts^TS		I	SEP / 98
Halofantrine or its salts^PDL		I	DEC / 13
Halofuginone or its salts^PDL	For veterinary use.	I	MAY / 18
Haloperidol^PDL		I	DEC / 13
Haloprogin		III	SEP / 98
Halothane^PDL		I	DEC / 13
Haloxazolam^TS		I	JUN / 02
Hemin^PDL		I	AUG / 18
Heparin and its salts.	except for topical use	II	SEP / 99
Hepatitis A vaccine		I	FEB / 02
Hepatitis B Adult vaccine		I	FEB / 02
Hepatitis B Pediatric vaccine		II	DEC / 98
Hepatitis B immune globulin		I	FEB / 02
Heptabarbital^C2		I	JUN / 02
Hetacillin or its salts or derivatives^PDL	For veterinary use.	I	DEC / 13
Hetastarch or its derivatives^PDL		I	DEC / 13
Hexachlorophene or its salts^PDL		I	DEC / 13
Hexacyclonate sodium^PDL		I	DEC / 13
Hexamethonium or its salts^PDL		I	DEC / 13
Hexethal^C2		I	JUN / 02
Hexobarbital^C2		I	JUN / 02
Histamine and its salts	except for topical use	II	SEP / 98
Histrelin or its salts^PDL		I	DEC / 13
Homatropine and its salts	for oral use in concentrations of 2 mg or less per dosage unit	II	SEP / 98
Homatropine and its salts	for ophthalmic or parenteral use or in preparations for oral use containing more than 2 mg per dosage unit	I	SEP / 98
Human insulin		II	SEP / 98
Hyaluronic acid and its salts	preparations in concentrations of 5% or more	II	SEP / 98
Hyaluronic acid or its salts^PDL	For veterinary use - when sold or recommended for administration by intra-articular injection to horses.	I	DEC / 13
Hyaluronidase		II	SEP / 98
Hydralazine or its salts^PDL		I	DEC / 13
Hydrocodone^N		I	JUN / 02
Hydrocortisone aceponate^PDL	For veterinary use.	I	DEC / 13
Hydrocortisone or hydrocortisone acetate	When sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in children under 2 years of age.	I	DEC / 14
Hydrocortisone or hydrocortisone acetate.	When sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing more than 30 g.	I	DEC / 14
Hydromorphinol^N		I	JUN / 02
Hydromorphone^N		I	JUN / 02
Hydroquinone or its derivatives^PDL	When sold in a concentration greater than 2% in preparations for topical use on the skin.	I	JUN / 19
Hydroquinone or its derivatives	When sold in a concentration less than or equal to 2% in preparations for topical use on the skin	II	JUN / 19
Hydroxocobalamin or its salts^PDL	When recommended as an antidote for cyanide poisoning.	I	DEC / 13
Hydroxychloroquine or its salts^PDL		I	DEC / 13
4- Hydroxycoumarin or its derivatives^PDL	Including but not limited to acenocoumarol when sold or recommended as anticoagulants.	I	DEC / 13
Hydroxyephedrine and its salts		II	SEP / 98
Hydroxypethidine^N		I	JUN / 02
Hydroxyurea^PDL		I	DEC / 13
Hydroxyzine or its salts or derivatives^PDL	Including but not limited to cetirizine and hydroxyzine hydrochloride. cetirizine or its salts when sold in concentration greater than 8.5 milligrams cetirizine per unit dose.	I	DEC / 13
Hyoscine and its salts and derivatives [scopolamine]	except Hyoscine butylbromide, when recommended for parenteral use	II	AUG / 16
Hyoscine butylbromide^PDL	When recommended for parenteral use.	I	AUG / 16
Hyoscyamine and its salts and derivatives	except for topical use	II	SEP / 98

49 result(s)

Print Friendly Export to CSV

Footnotes

C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
C4: drug is in the Controlled Drugs and Substances Act
C5: drug is in the Regulations Under CDSA
CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
NR: drug has not been reviewed by NDSAC
PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
U: drug has been reviewed by NDSAC and is unscheduled

National Drug Schedules

Search: National Drug Schedules

49 result(s)

Footnotes